According to Jin10, Beda Pharmaceutical shares opened sharply lower and quickly hit the daily limit down, closing at 55.72 yuan per share, down 20%. EyePoint said on August 17 that its ophthalmic drug vorolanib sustained-release formulation DURAVYU (EYP-1901) failed to meet the prespecified primary efficacy endpoint in the global phase III LUGANO trial for wet age-related macular degeneration, and EYPT fell 66.98% overnight in U.S. trading. Beda Pharmaceutical said its overseas subsidiary has worked with EYPT for many years, that one phase III clinical result for vorolanib sustained-release formulation did not meet expectations, that another result is expected in October, and that the drug has not been launched and has no impact on the company's existing business. The company also said the matter has not triggered mandatory disclosure standards for listed companies and that it is in a silent period before its half-year report disclosure.